| Literature DB >> 31766215 |
Mohamed S H Hassan1, Davor Ojkic2, Carla S Coffin3, Susan C Cork1, Frank van der Meer1, Mohamed Faizal Abdul-Careem1.
Abstract
Infectious bronchitis virus (IBV) infection in chickens can lead to an economically important disease, namely, infectious bronchitis (IB). New IBV variants are continuously emerging, which complicates vaccination-based IB control. In this study, five IBVs were isolated from clinical samples submitted to a diagnostic laboratory in Ontario, Canada, and subjected to detailed molecular characterization. Analysis of the spike (S)1 gene showed that these five IBVs were highly related to the Delmarva (DMV/1639) strain (~97.0% nucleotide sequence similarity) that was firstly isolated from an IB outbreak in the Delmarva peninsula, United States of America (USA), in 2011. However, the complete genomic sequence analysis showed a 93.5-93.7% similarity with the Connecticut (Conn) vaccine strain, suggesting that Conn-like viruses contributed to the evolution of the five Canadian IBV/DMV isolates. A SimPlot analysis of the complete genomic sequence showed evidence of recombination for at least three different IBV strains, including a Conn vaccine-like strain, a 4/91 vaccine-like strain, and one strain that is yet-unidentified. The unidentified strain may have contributed the genomic regions of the S, 3, and membrane (M) genes of the five Canadian IBV/DMV isolates. The study outcomes add to the existing knowledge about involvement of recombination in IBV evolution.Entities:
Keywords: Canada; Infectious bronchitis virus (IBV); chicken; complete genome sequence; phylogenetic analysis; recombination
Mesh:
Substances:
Year: 2019 PMID: 31766215 PMCID: PMC6893544 DOI: 10.3390/v11111054
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
History of the five infectious bronchitis virus (IBV) isolates used in this study.
| IBV Isolate | Type of Sample | Commodity | Age | Size of the Flock | Main Complaint |
|---|---|---|---|---|---|
| IBV/Ck/Can/17-035614 | Cecal tonsils | Layers | 6 weeks | 100,000 | Uneven flock |
| IBV/Ck/Can/17-036989 | Kidneys | Layers | 22 weeks | NA | Drop in egg production |
| IBV/Ck/Can/18-048192T | Trachea | Broilers | NA | NA | NA |
| IBV/Ck/Can/18-048430 | Tracheal swab | Broilers | 34 days | 9408 | Routine sampling |
| IBV/Ck/Can/18-049707 | Cecal tonsils | Broiler breeders | 41 weeks | 20,358 | Increased mortality |
NA = Not available.
Figure 1Randomized accelerated maximum likelihood (RAxML) phylogenetic tree based on the complete nucleotide sequences of S1 genes of our five IBV isolates and 86 reference sequences. All genotypes of representative IBV strains are indicated on the right side. Our five IBV isolates are marked in red color.
Percent S1 amino acid and nucleotide sequence identity values for the five IBV isolates used in this study and other strains that are circulating in Canada.
| Nucleotide Identity (%) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18-048192T | 18-049707 | 18-048430 | 17-036989 | 17-035614 | DMV/1639 | PA/Wolg/98 | Qu-mv | Conn | Mass | 4/91 | CAL1737 | CU_82792 | DE/072 | ||
|
|
| 99.5 | 99.8 | 99.4 | 99.7 | 96.5 | 90.1 | 78.8 | 77.2 | 77.2 | 76.0 | 76.5 | 56.4 | 55.8 | |
|
| 99.3 | 99.6 | 99.9 | 99.7 | 96.5 | 90.1 | 78.6 | 77.2 | 77.2 | 75.8 | 76.2 | 56.3 | 55.6 | ||
|
| 99.6 | 99.3 | 99.5 | 99.8 | 96.4 | 89.9 | 78.7 | 77.2 | 77.2 | 75.3 | 76.4 | 56.4 | 55.8 | ||
|
| 99.1 | 99.8 | 99.1 | 99.6 | 96.4 | 90.0 | 78.5 | 77.2 | 77.2 | 75.7 | 75.5 | 55.3 | 55.6 | ||
|
| 99.4 | 99.4 | 99.6 | 99.3 | 96.7 | 89.9 | 78.6 | 77.3 | 77.3 | 75.8 | 76.1 | 56.3 | 55.6 | ||
|
| 94.8 | 95.2 | 95.0 | 95.0 | 95.3 | 91.1 | 79.7 | 78.4 | 78.4 | 76.2 | 75.1 | 56.0 | 55.3 | ||
|
| 87.5 | 87.3 | 87.1 | 87.1 | 87.1 | 87.5 | 79.6 | 78.6 | 78.6 | 76.3 | 76.1 | 56.5 | 56.0 | ||
|
| 76.3 | 76.1 | 76.1 | 75.9 | 75.9 | 75.9 | 76.1 | 78.6 | 79.3 | 77.0 | 75.9 | 57.2 | 56.8 | ||
|
| 75.5 | 76.9 | 75.6 | 75.5 | 75.6 | 75.3 | 75.7 | 74.3 | 95.1 | 77.6 | 80.3 | 58.7 | 57.9 | ||
|
| 73.0 | 73.3 | 73.2 | 73.2 | 73.3 | 73.4 | 73.9 | 74.2 | 90.3 | 78.3 | 80.6 | 58.6 | 57.9 | ||
|
| 75.5 | 75.5 | 75.3 | 75.3 | 75.3 | 74.7 | 74.4 | 75.1 | 73.9 | 73.8 | 77.2 | 56.2 | 55.8 | ||
|
| 72.8 | 72.8 | 72.7 | 72.7 | 72.8 | 71.2 | 71.6 | 72.3 | 77.6 | 78.3 | 74.4 | 57.6 | 57.2 | ||
|
| 45.2 | 45.5 | 45.4 | 45.5 | 45.4 | 44.6 | 46.1 | 48..0 | 48.4 | 49.3 | 45.3 | 47.1 | 96.3 | ||
|
| 45.7 | 45.9 | 45.9 | 45.9 | 45.9 | 45.0 | 46.6 | 47.8 | 48.8 | 49.5 | 45.5 | 48.0 | 93.6 | ||
Our five IBV isolates are denoted in boldface.
Figure 2Sequence alignment of open reading frame (ORF) 6b from our five IBV isolates. The deletion in gene 6b of isolate IBV/Ck/Can/18-048192T results in a truncated 6b protein. Sequences of isolates IBV/Ck/Can/17-035614, IBV/Ck/Can/17-036989, IBV/Ck/Can/18-048430, and IBV/Ck/Can/18-049707, as representatives of the normal 6b gene, were compared. The ATGs with a single underline in boldface are the start codons of 6b gene. TGA and TAGs in boxes are the termination codons of 6b gene in IBV/Ck/Can/18-048192T and the other four isolates, respectively. A 13-nucleotide sequence was deleted in isolate IBV/Ck/Can/18-048192T (represented as –).
Genome features of the five IBV isolates used in this study.
| IBV/Ck/Can/17-035614 | IBV/Ck/Can/17-036989 | IBV/Ck/Can/18-048192T | IBV/Ck/Can/18-048430 | IBV/Ck/Can/18-049707 | |
|---|---|---|---|---|---|
|
| 1–530 (530 nt) | 1–528 (528 nt) | 1–528 (528 nt) | 1–528 (528 nt) | 1–528 (528 nt) |
|
| 531–12,419 (11889 nta-3962 aab) | 529–12,417 (11889 nt-3962 aa) | 529–12,360 (11832 nt-3943 aa) | 529–12,393 (11865 nt-3954 aa) | 529–12,417 (11889 nt-3962 aa) |
|
| 531–20,452 (19922 nt-6639 aa) | 529–20,450 (19922 nt-6639 aa) | 529–20,393 (19865 nt-6620 aa) | 529–20,426 (19898 nt-6631 aa) | 529–20,450 (19922 nt-6639 aa) |
|
| 20,403–23,903 (3501 nt-1166 aa) | 20,401–23,901 (3501 nt-1166 aa) | 20,344–23,844 (3501 nt-1166 aa) | 20,377–23,877 (3501 nt-1166 aa) | 20,401–23,901 (3501 nt-1166 aa) |
|
| 23,903–24,076 (174 nt-57 aa) | 23,901–24,074 (174 nt-57 aa) | 23,844–24,017 (174 nt-57 aa) | 23,877–24,050 (174 nt-57 aa) | 23,901–24,074 (174 nt-57 aa) |
|
| 24,076–24,270 (195 nt-64 aa) | 24,074–24,268 (195 nt-64 aa) | 24,017–24,211 (195 nt-64 aa) | 24,050–24,244 (195 nt-64 aa) | 24,074–24,268 (195 nt-64 aa) |
|
| 24,251–24,580 (330 nt-109 aa) | 24,249–24,578 (330 nt-109 aa) | 24,192–24,521 (330 nt-109 aa) | 24,225–24,554 (330 nt-109 aa) | 24,249–24,578 (330 nt-109 aa) |
|
| 24,552–25,229 (678 nt-225 aa) | 24,550–25,227 (678 nt-225 aa) | 24,493–25,170 (678 nt-225 aa) | 24,526–25,203 (678 nt-225 aa) | 24,550–25,227 (678 nt-225 aa) |
|
| 25,230–25,514 (285 nt-94 aa) | 25,228–25,512 (285 nt-94 aa) | 25,171–25,455 (285 nt-94 aa) | 25,204–25,488 (285 nt-94 aa) | 25,228–25,512 (285 nt-94 aa) |
|
| 25,435–25,605 (171 nt-56 aa) | 25,433–25,603 (171 nt-56 aa) | 25,376–25,546 (171 nt-56 aa) | 25,409–25,579 (171 nt-56 aa) | 25,433–25,603 (171 nt-56 aa) |
|
| 25,589–25,786 (198 nt-65 aa) | 25,587–25,784 (198 nt-65 aa) | 25,530–25,727 (198 nt-65 aa) | 25,563–25,760 (198 nt-65 aa) | 25,587–25,784 (198 nt-65 aa) |
|
| 25,783–26,031 (249 nt-82 aa) | 25,781–26,029 (249 nt-82 aa) | 25,724–25,972 (249 nt-82 aa) | 25,757–26,005 (249 nt-82 aa) | 25,781–26,029 (249 nt-82 aa) |
|
| 25,974–27,203 (1230 nt-409 aa) | 25,972–27,201 (1230 nt-409 aa) | 25,915–27,144 (1230 nt-409 aa) | 25,948–27,177 (1230 nt-409 aa) | 25,972–27,201 (1230 nt-409 aa) |
|
| 27,212–27,436 (225 nt-74 aa) | 27,210–27,434 (225 nt-74 aa) | 27,153–27296 (144 nt-47 aa) | 27,186–27,410 (225 nt-74 aa) | 27210–27,434 (225 nt-74 aa) |
|
| 27,437–27,710 (274 nt) | 27,435–27,708 (274 nt) | 27,297–27,638 (342 nt) | 27,411–27,684 (274 nt) | 27,435–27,708 (274 nt) |
a: Nucleotide length; b: Amino acid length.
Figure 3Alignment of the complete genome sequences of our five IBV isolates, the Connecticut vaccine, and 4/91 vaccine strains, which was performed using MAFFT. Nucleotide sequence disagreements at the indicated positions are shown in black, while nucleotide sequence agreements are shown in gray.
Figure 4Alignment of the complete genome sequences of isolate GA9977/2019, the Connecticut vaccine, and 4/91 vaccine strains, which was performed using MAFFT. Nucleotide sequence disagreements at indicated positions are shown in black, while nucleotide sequence agreements are shown in gray.
Figure 5(a) Recombination analysis by SimPlot of the complete genome sequences of IBV/Ck/Can/18-049707, the Connecticut vaccine, and the 4/91 vaccine strains. Breakpoints are indicated by the vertical red lines. The SimPlot was created using a window size of 1000 nt and a step size of 50 nt. Isolate IBV/Ck/Can/18-049707 was used as the query sequence. (b) Percentages of nucleotide sequence identity among our five IBV isolates, the Connecticut vaccine, the 4/91 vaccine, and H120 (as a representative of the Massachusetts type, the second major live vaccine available in Canada) according to the genome fragments indicated by SimPlot. Genome positions were determined according to isolate IBV/Ck/Can/18-049707 in the alignment. (c) Phylogenetic analysis of genome positions 1–1911, 1912–3735, 3736–12043, 12044–20120, 20121–25100, and 25,101–3′ end of the complete genome among our five IBV isolates, Connecticut vaccine, 4/91 vaccine, Arkansas DPI (GQ504720), H120 (FJ888351), JMK (GU393338), Iowa 97 (GU393337), Delaware 072 (Gu393332) and ck/CH/LDL/05II (kx364298). The trees were constructed using the maximum likelihood method in PhyML. Our five IBV isolates are marked in red color.